Open AccessJanus kinase inhibitors in the treatment of psoriatic arthritis
Author(s) -
E. Yu. Loginova,
Т. В. Коротаева
Publication year - 2022
Publication title -
sovremennaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 2310-158X
pISSN - 1996-7012
DOI - 10.14412/1996-7012-2022-1-7-13
Subject(s) - tofacitinib , psoriatic arthritis , medicine , janus kinase , observational study , oncology , randomized controlled trial , clinical trial , janus kinase inhibitor , arthritis , pharmacology , dermatology , rheumatoid arthritis , receptor
The article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis (PsA). The results of randomized placebocontrolled clinical trials and long-term observational studies indicate the high efficacy and safety of using TOFA and UPA in the treatment of patients with PsA who are resistant to synthetic DMARDs and tumor necrosis factor-α inhibitors. The information obtained so far allows us to recommend JAK inhibitors as a new pathogenetic approach to the treatment of PsA.